文献速递造血干细胞移植与细胞治疗

伊他替尼联合糖皮质激素对比安慰剂联合糖皮质激素用于急性移植物抗宿主病初始治疗的疗效与安全性(GRAVITAS-301):一项随机、多中心、双盲、3期试验

Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2022-01-01

GRAVITAS-301是一项在19个国家129家医院开展的随机双盲3期试验,439例II-IV级急性GVHD患者按1:1接受口服伊他替尼200mg或安慰剂,均联合糖皮质激素。第28天总缓解率伊他替尼组74% vs 安慰剂组66%(OR 1.45,95%CI 0.96-2.20;P=0.078),未达预设显著性水平。

要点

  • 第28天ORR伊他替尼组74% vs 安慰剂组66%,OR 1.45(95%CI 0.96-2.20),P=0.078,未达预设显著性。
  • 3级及以上不良事件发生率伊他替尼组86% vs 安慰剂组82%。
  • 治疗相关死亡伊他替尼组3/215例(1%)vs 安慰剂组4/216例(2%)。

核心结论

  • 在糖皮质激素基础上加用伊他替尼对比安慰剂,第28天ORR的改善未达预设显著性水平。
  • 进一步研究可能为选择性JAK1抑制治疗急性GVHD的效用提供更多见解。

研究设计与样本

  • GRAVITAS-301为国际、双盲、适应性(组序贯设计)3期研究,在19个国家的129家医院和社区诊所开展。
  • 纳入年龄≥18岁、因血液系统恶性肿瘤接受异基因HSCT后发生II-IV级急性GVHD、且已接受不超过2天全身糖皮质激素的患者。
  • 患者按临床标危或高危急性GVHD分层,经中央交互式语音应答系统1:1随机分配至口服伊他替尼200mg每日一次或安慰剂每日一次,均联合糖皮质激素。
  • 主要终点为第28天总缓解率(ORR),定义为治疗开始后28天完全缓解、非常好的部分缓解或部分缓解的患者比例。
  • 样本量确定时,第28天ORR较标准治疗绝对改善16%被视为有临床意义;疗效分析在意向治疗人群中进行,安全性分析包括至少接受一剂研究药物的患者。

主要发现

  • 2017年7月19日至2019年10月3日,439例患者随机分配至伊他替尼联合糖皮质激素组(n=219)或安慰剂联合糖皮质激素组(n=220)。
  • 173例(39%)为女性,390例(89%)为白人;基线时439例中107例(24%)为临床高危急性GVHD(伊他替尼组51/219例[23%],安慰剂组56/220例[25%])。
  • 第28天ORR伊他替尼组为74%(95%CI 67.6-79.7;162/219;完全缓解53%[116/219]),安慰剂组为66%(95%CI 59.7-72.6;146/220;完全缓解40%[89/220]),OR 1.45(95%CI 0.96-2.20;双侧P=0.078)。
  • 3级及以上不良事件伊他替尼组185/215例(86%)vs 安慰剂组178/216例(82%),最常见包括血小板减少或血小板计数降低(78例[36%] vs 68例[31%])、中性粒细胞减少或中性粒细胞计数降低(49例[23%] vs 45例[21%])、贫血(42例[20%] vs 26例[12%])和高血糖(26例[12%] vs 28例[13%])。
  • 治疗相关死亡伊他替尼组3/215例(1%)vs 安慰剂组4/216例(2%)。

关键数值与推荐

  • 第28天ORR伊他替尼组74%(95%CI 67.6-79.7;162/219)vs 安慰剂组66%(95%CI 59.7-72.6;146/220),OR 1.45(95%CI 0.96-2.20;双侧P=0.078)。
  • 第28天完全缓解率伊他替尼组53%(116/219)vs 安慰剂组40%(89/220)。
  • 3级及以上不良事件伊他替尼组86%(185/215)vs 安慰剂组82%(178/216)。
  • 治疗相关死亡伊他替尼组1%(3/215)vs 安慰剂组2%(4/216)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出第28天ORR的改善未达预设显著性水平。
  • 原文结论指出进一步研究可能为选择性JAK1抑制治疗急性GVHD的效用提供更多见解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute graft-versus-host disease (GVHD) is a common and life-threatening complication of allogeneic haematopoietic stem cell transplantation (HSCT); there is an urgent unmet need for effective therapies. We aimed to evaluate the Janus kinase 1 inhibitor itacitinib versus placebo, both in combination with corticosteroids, for initial treatment of acute GVHD. METHODS: GRAVITAS-301 was an international, double-blind, adaptive (group sequential design) phase 3 study conducted at 129 hospitals and community practices in 19 countries. Eligible patients were aged 18 years or older, had previously received allogeneic HSCT for a haematological malignancy, developed grades II-IV acute GVHD, and received up to 2 days of systemic corticosteroids. Patients were stratified by clinical standard-risk or high-risk acute GVHD and randomly assigned (1:1), via a centralised interactive voice response system, to receive either oral itacitinib (200 mg) or placebo once daily, both in addition to corticosteroids. The primary endpoint was overall response rate (ORR) at day 28 (defined as the proportion of patients with complete response, very good partial response, or partial response 28 days after the start of treatment). For sample size determination, an absolute improvement in ORR at day 28 over standard therapy of 16% was considered clinically meaningful. Efficacy analyses were performed in the intention-to-treat population; safety analyses included patients who received at least one dose of study drug. GRAVITAS-301 is registered with ClinicalTrials.gov (NCT03139604) and is complete. FINDINGS: Between July 19, 2017, and Oct 3, 2019, 439 patients were randomly assigned to receive either itacitinib plus corticosteroids (n=219; itacitinib group) or placebo plus corticosteroids (n=220; placebo group). 173 (39%) patients were female and 390 (89%) were White. At baseline, 107 (24%) of 439 patients (itacitinib 51 [23%] of 219; placebo 56 [25%] of 220) had clinical high-risk acute GVHD. The ORR at day 28 was 74% (95% CI 67·6-79·7; 162 of 219; complete response 53% [116 of 219]) for itacitinib and 66% (59·7-72·6; 146 of 220; complete response, 40% [89 of 220]) for placebo (odds ratio for ORR 1·45, 95% CI 0·96-2·20; two-sided p=0·078). Grade 3 or worse adverse events occurred in 185 (86%) of 215 itacitinib recipients and 178 (82%) of 216 placebo recipients, and most commonly included thrombocytopenia or platelet count decreased (78 [36%] vs 68 [31%]), neutropenia or neutrophil count decreased (49 [23%] vs 45 [21%]), anaemia (42 [20%] vs 26 [12%]), and hyperglycaemia (26 [12%] vs 28 [13%]). Treatment-related deaths occurred in three of 215 patients (1%) in the itacitinib group and four of 216 (2%) in the placebo group. INTERPRETATION: The observed improvement in ORR at day 28 with the addition of itacitinib versus placebo to corticosteroids did not reach the prespecified significance level. Further studies might provide additional insight into the utility of selective JAK1 inhibition for the treatment of acute GVHD. FUNDING: Incyte.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Zeiser R, Socié G, Schroeder MA, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022. PMID: 34971577. doi:10.1016/S2352-3026(21)00367-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。